S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

from OncLive® On Air · host OncLive® On Air

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer, key efficacy and safety data from the EV-302 trial, and future directions in urothelial cancer research.

Episode metadata supplied by the publisher feed · Published Feb 12, 2024

Embed this episode

Attribution link and audio player

Ready to play

S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

0:00 9:06

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 9 minutes long.

When was this OncLive® On Air episode published?

This episode was published on February 12, 2024.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!